Conversion of a portion of the loans from Highbridge and Whitebox and Information on the total number of voting rights (denominator)

Liege, Belgium, 10 August 2022 – 18:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra“), a company dedicated to Women’s Health, today announces that, following the first drawdown by the Company under the loan facility concluded with funds managed by Highbridge Capital Management, LLC (“Highbridge“) and funds managed by Whitebox Advisors, LLC (“Whitebox“, and together with Highbridge, each a “Lender”), a first portion of the commitment fee due by the Company was settled in new shares, and a first portion of the loans were contributed in kind by the Lenders against the issuance of new shares.